Altimmune posts higher than expected Q3 loss
ALT•ALT•ALT•ALT•Altimmune reported a Q3 net loss of $31.61 million, or $0.15 per share, missing analyst expectations of $25.48 million and $0.14 per share. The company ended the quarter with $480 million in cash, cash equivalents and investments.
Altimmune’s Q3 net loss was $31.61 million, compared with analysts’ $25.48 million estimate, and its loss per share of $0.15 missed the $0.14 estimate. Operating expenses were $35.71 million, with higher research and development costs driven primarily by its PERFORMA Phase 3 MASH trial and RESTORE Phase 2 ALD trial, and higher general and administrative costs tied mainly to compensation and professional services.
The PERFORMA trial is progressing as planned, with 52-week topline data expected in 2029. An FDA end-of-Phase 2 meeting for the AUD program is scheduled for December 2026, and topline data from the RESTORE trial is expected in the second half of 2027.
